UK mid-cap stocks look forward to life after lockdown
The FTSE 250 hit an all-time high at the end of last week, as investors look to a post-lockdown recovery.

British mid-cap shares are enjoying the prospect of life after lockdown, says Danni Hewson of AJ Bell. The FTSE 250 has soared by 63.5% since its nadir in March last year, and hit an all-time high at the end of last week. Shares in everything from cruise ship business Carnival to shopping-centre owner Hammerson registered double-digit gains in the space of seven days.
FTSE 100 plods along
Investors in the blue-chip FTSE 100 are not feeling so jubilant, says Julien Ponthus for Reuters. The index is up by 4.5% so far this year but has underperformed other major markets for yet another quarter. It is still 7.5% short of its February 2020 level; trading around 6,880 points this week it also remains below the 7,000 level that it fell through as Covid-19 took hold.
The British market is often described as “unloved”, but perhaps “abandoned” would be a better word, says Ross Clark in The Spectator. The FTSE 100 is up by just 10% since the 2016 referendum. Over the same period the Hang Seng advanced by 42%, the Dax by 44% and the Dow Jones index by 88%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Yet more and more fund managers are now betting that the blue-chip index’s stodgy energy and financial businesses “have been hammered well beyond [what]they deserved, so there is bound to be a correction in their favour”. Funds network Calastone reports that £600m of net investment flowed into UK equity funds in March, compared with £151m in February, says David Brenchley in The Sunday Times.
The UK economy was particularly badly hit by the pandemic, with GDP contracting by 9.8% last year, compared with a 6.6% fall in the eurozone and a 3.5% decline in the US. That gives it more room to rebound. Indeed, the International Monetary Fund (IMF) thinks the UK is set to expand at its fastest pace since the late 1980s over the next two years, says Liam Halligan in The Daily Telegraph. While Britain’s first-quarter lockdown will see it lag the US this year, come 2022 it could be the fastest growing major developed economy in the world.
FTSE 250’s time to shine
The FTSE 250 is best-placed to gain from the UK rebound, says Laith Khalaf of AJ Bell. The FTSE 100 is very international: roughly 75% of blue-chip earnings come from overseas. That earnings split falls to 50% domestic and 50% overseas for the FTSE 250, not a “pure barometer of the health of the UK economy”, but closer than the FTSE 100. Since the turn of the century the mid-cap index has “wiped the floor with the big blue chips of the FTSE 100”. The FTSE 250 has returned 533% over the past 20 years, far superior to the FTSE 100’s 154%, notes Brenchley.
Fund managers punting on the blue chips are still hopeful that their time will come, says Ponthus. FTSE 100 shares trade on 14.2 times forward earnings, compared with 17.9 in the eurozone and the global average of approximately 19.5. Throw in an attractive 3.1% average dividend yield and UK shares are, as James Henderson of Janus Henderson puts it, “very, very cheap”.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Trump’s tariffs: how should the UK respond?
Every right-thinking person knows that free trade is a surer route to the wealth of nations than protectionism. So, what is Trump thinking?
By Stuart Watkins
-
Lloyds axes foreign currency fees for Club Lloyds customers
Club Lloyds customers will be able to withdraw their money abroad without incurring any extra fees.
By Daniel Hilton
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Bargain Britain boasts both value and momentum
Interview Ian Lance, manager of the Temple Bar Investment Trust, tells Andrew Van Sickle that the outlook for UK stocks has improved and healthy long-term returns are in prospect
By Andrew Van Sickle
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine